to check the protective antibody titre levels in actively participating already vaccinated dental studentsand check for the need of booster dose in health care workers

Seroprevalence of Anti- HBs titre levels in Hepatitis B vaccinated dental students. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094396

Enrollment

Registered

2025-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: This is an observational study No intervention or comparator agent will be administered: Participants will undergo a one-time blood sample collection (5 ml) for assessment of anti-HBs t

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who have completed 3 doses of single-antigen recombinant hepatitis B vaccine, usually administered on a 3-dose schedule at 0, 1, and 6 months. Subjects who don?t give the history of hepatitis B exposure previously Subjects who are willing to be the part of the study

Exclusion criteria

Exclusion criteria: subjects who have not previously been vaccinated with hepatitis B primary vaccination schedule Subjects who are not willing to be the part of the study Subjects with previous history of hepatitis B infection

Design outcomes

Primary

Measure	Time frame
If the level of anti HBs is greater than 10mIU/ml the subject can be is considered to have seroprotective titres of antibodies and no further hepatitis B vaccine booster doses are required If the level of Anti HBs is less than 10mIU/ml then subject is defined as having suboptimal seroprotective titres of antibodies and hepatitis B vaccine booster doses are requiredTimepoint: If the level of anti HBs is greater than 10mIU/ml the subject can be is considered to have seroprotective titres of antibodies and no further hepatitis B vaccine booster doses are required If the level of Anti HBs is less than 10mIU/ml then subject is defined as having suboptimal seroprotective titres of antibodies and hepatitis B vaccine booster doses are required	—

Measure

Time frame

If the level of anti HBs is greater than 10mIU/ml the subject can be is considered to have seroprotective titres of antibodies and no further hepatitis B vaccine booster doses are required If the level of Anti HBs is less than 10mIU/ml then subject is defined as having suboptimal seroprotective titres of antibodies and hepatitis B vaccine booster doses are requiredTimepoint: If the level of anti HBs is greater than 10mIU/ml the subject can be is considered to have seroprotective titres of antibodies and no further hepatitis B vaccine booster doses are required If the level of Anti HBs is less than 10mIU/ml then subject is defined as having suboptimal seroprotective titres of antibodies and hepatitis B vaccine booster doses are required

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactEitisha Gupta

Meenakshi Ammal Dental College and Hospital, Chennai

drkeerthana.omfs@madch.edu.in9790885444

Outcome results